Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | PPARG | P37231 | 2/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15409809 | 0.85 | ALDH1A1 (0.59) | ALDH1A1PPARGMAPK14MAPTKDM4E | |
| SCHEMBL15411133 | 0.85 | MAPT (0.55) | ALDH1A1PPARGMAPTKDM4ERAB9A | |
| SCHEMBL15412060 | 0.84 | ALDH1A1 (0.61) | ALDH1A1PPARGMAPTKDM4EGAA | |
| SCHEMBL15410036 | 0.82 | ALDH1A1 (0.56) | ALDH1A1MAPK14MAPTKDM4EGAA | |
| SCHEMBL15409916 | 0.81 | KDM4E (0.47) | ALDH1A1PPARGMAPK14NPC1KDM4E | |
| SCHEMBL15410597 | 0.81 | ALDH1A1 (0.55) | ALDH1A1PPARGMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL21715473 | 0.78 | MAPT (0.63) | ALDH1A1MAPTNPC1KDM4ESMN1; SMN2 | |
| SCHEMBL15411332 | 0.78 | MAPT (0.55) | ALDH1A1PPARGMAPTKDM4ERAB9A | |
| SCHEMBL15411335 | 0.78 | ALDH1A1 (0.55) | ALDH1A1MAPK14MAPTGAAMEN1 | |
| SCHEMBL15411672 | 0.77 | MAPT (0.62) | ALDH1A1MAPTKDM4ESMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48140-E1 | Furanone derivative | CARNA BIOSCIENCES, INC. (JP) | 2020-08-04 | — | — | US | disclosed |
| EP-2692728-B1 | NOVEL FURANONE DERIVATIVE | CARNA BIOSCIENCES INC (JP) | 2018-07-04 | — | — | EP | disclosed |
| US-RE46815-E1 | Furanone derivative | CARNA BIOSCIENCES, INC. (JP) | 2018-05-01 | — | — | US | disclosed |
| US-8742113-B2 | Furanone derivative | SBI BIOTECH CO., LTD. (JP) | 2014-06-03 | — | — | US | disclosed |
| EP-2692728-A1 | NOVEL FURANONE DERIVATIVE | SBI Biotech Co., Ltd. (JP) | 2014-02-05 | — | — | EP | disclosed |
| US-20140018533-A1 | NOVEL FURANONE DERIVATIVE | CARNA BIOSCIENCES, INC. (JP) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018533-A1 | NOVEL FURANONE DERIVATIVE | CYP11B1, OXER1, CYP11B2 | ALDH1A1 345/4885PPARG 1958/4885MAPK14 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.